Table 1. Demographic characteristics of users who received atypical antipsychotics via the Brazilian National Health System, their national region of residence and year of entry into the database, Brazil, 2008-2017.
| Variables | Children and adolescents (up to 18 years old) | Adults (19 to 59 years old) | Older adults (60 years and older) | Total |
|---|---|---|---|---|
| N = 68,584 (%) | N = 522,071 (%) | N = 168,999 (%) | N = 759,654 (%) | |
| Sex | ||||
| Female | 21,542 (31.4) | 255,903 (49.1) | 106,583 (63.1) | 384,028 (50.5) |
| Male | 47,042 (68.6) | 266,168 (50.9) | 62,416 (36.9) | 375,626 (49.5) |
| Age group (full years) | ||||
| ≤ 10 | 16,344 (23.8) | 16,344 (2.2) | ||
| 11-18 | 52,240 (76.2) | 52,240 (6.9) | ||
| 19-29 | 133,714 (25.6) | 133,714 (17.6) | ||
| 30-39 | 146,518 (28.1) | 146,518 (19.3) | ||
| 40-49 | 137,630 (26.4) | 137,630 (18.2) | ||
| 50-59 | 104,209 (19.9) | 104,209 (13.7) | ||
| 60-69 | 60,524 (35.8) | 60,524 (7.9) | ||
| 70-79 | 54,794 (32.4) | 54,794 (7.2) | ||
| 80-89 | 45,138 (26.7) | 45,138 (5.9) | ||
| 90-99 | 8,543 (5.1) | 8,543 (1.1) | ||
| Race/skin color (self-reported) | ||||
| White | 8,241 (12.0) | 55,274 (10.6) | 24,641 (14.6) | 88,156 (11.1) |
| Black | 773 (1.1) | 5,809 (1.1) | 1,430 (0.8) | 8,012 (1.0) |
| Mixed race | 5,620 (8.2) | 34,782 (6.6) | 8,612(5.1) | 49,014 (6.2) |
| Asian | 1,536 (2.2) | 12,045 (2.3) | 2,783 (1.6) | 16,364 (2.1) |
| Indigenous | 33 (0.1) | 93 (0.1) | 20 (0.1) | 146 (0.1) |
| No information | 52,381 (76.4) | 414,068 (79.3) | 131,513 (77.8) | 633,962 (79.5) |
| National region of residence | ||||
| North | 1,855 (2.7) | 14,313 (2.7) | 2,067 (1.2) | 18,235 (2.4) |
| Northeast | 14,312 (20.8) | 104,933 (20.1) | 23,416 (13.9) | 142,661 (18.8) |
| Southeast | 39,681 (57.9) | 296,424 (56.8) | 121,524 (71.9) | 457,629 (60.3) |
| South | 8,829(12.9) | 66,253 (12.7) | 13,133 (7.7) | 88,215 (11.6) |
| Midwest | 3,907 (5.7) | 40,148 (7.7) | 8,859 (5.3) | 52,914 (6.9) |
| Year of entry into the pharmaceutical assistance program - CEAFa | ||||
| 2008 | 12,168 (17.7) | 118,427 (22.7) | 24,640 (14.6) | 155,235 (20.4) |
| 2009 | 6,116 (8.9) | 46,750 (8.9) | 13,191 (7.8) | 66,057 (8.7) |
| 2010 | 6,321 (9.2) | 43,510 (8.3) | 16,141 (9.6) | 65,972 (8.7) |
| 2011 | 6,545 (9.5) | 44,545 (8.5) | 15,087 (8.9) | 66,177 (8.7) |
| 2012 | 5,798 (8.5) | 37,571 (7.2) | 12,960 (7.7) | 56,329 (7.4) |
| 2013 | 5,864 (8.6) | 41,059 (7.9) | 14,600 (8.6) | 61,523 (8.1) |
| 2014 | 6,169 (9.0) | 41,162 (7.9) | 16,056 (9.5) | 63,387 (8.4) |
| 2015 | 6,991 (10.2) | 53,317 (10.2) | 19,589 (11.6) | 79,897 (10.5) |
| 2016 | 6,717 (9.8) | 53,678 (10.3) | 19,499 (11.5) | 79,894 (10.5) |
| 2017 | 5,895 (8.6) | 42,052 (8.1) | 17,236 (10.2) | 65,183 (8.6) |
a) CEAF: Specialized Component of Pharmaceutical Assistance/Department of Pharmaceutical Assistance, Secretariat of Science and Technology and Strategic Inputs, Ministry of Health.